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Abbreviations 
 
EMSA electrophoretic mobility shift assay 
eNOS endothelial nitric oxide synthase 
Epo erythropoietin 
FiO2 fraction of inspired oxygen 
fR respiratory frequency 
HIF hypoxia-inducible factor 
NO nitric oxide 
PCR polymerase chain reaction 
PHD prolyl-hydroxylase 
rhEpo recombinant human erythropoietin 
RV dP/dtmax maximal rate of right ventricular pressure increase 
RVSP right ventricular systolic pressure 
tg6 transgenic mouse line overexpressing human Epo 
 cDNA 
VE minute ventilation 
VT tidal volume 
wt wild-type mouse 
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1. Summary 
 
Besides enhancing erythropoiesis, erythropoietin (Epo) has several tissue-protective 
effects. We tested the impact of elevated Epo plasma levels on pulmonary 
hypertension and made use of the transgenic mouse line tg6 chronically 
overexpressing Epo and reaching haematocrit levels of up to 89%. Mice were 
exposed to normobaric hypoxia (≥ 7% O2) for up to 24 h. Haemodynamic 
measurements showed a smaller increase in pulmonary artery pressure in hypoxic 
tg6 mice compared to wild type (wt) controls. Plethysmographic analysis and blood 
gas determination revealed impaired ventilation and reduced blood oxygenation. 
Hypoxic tg6 lung tissue showed a more pronounced stabilisation of HIF-1α and -2α 
as well as HIF binding activity. When comparing hypoxic lung tissue of tg6 and wt 
animals we did not observe altered mRNA expression of all three prolyl hydroxylases 
that are important modulators of HIF stabilisation. Interestingly, eNOS mRNA level 
was elevated in tg6 mice and the NO synthase inhibitor L-NAME reduced the 
elevation of HIF-1α and -2α protein levels in the lung of hypoxic tg6 mice to a higher 
extent than in wt. We also replaced tg6 by wt animals that were acutely treated with 
recombinant human Epo. As we did not observe any difference between Epo-treated 
and untreated wt mice, we conclude that the protective effects observed in hypoxic 
tg6 mice are not due to acute effects of Epo, but the result of adaptive mechanisms 
responding to Epo-induced chronic excessive erythrocytosis. 
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2. Zusammenfassung 
 
Erythropoietin (Epo) hat, neben der Erythropoiese, verschiedene Gewebe-
schützende Effekte. Wir haben den Einfluss von erhöhten Epo-Werten im Plasma auf 
die pulmonäre Hypertonie untersucht und das Modell der transgenen Maus (tg6) mit 
chronischer Überexpression von Epo und einem Hämatokrit von bis zu 89% 
verwendet. Die Mäuse wurden bis zu 24 h lang einer normobaren Hypoxie (≥ 7% O2) 
ausgesetzt. Hämodynamische Messungen zeigten einen kleineren Anstieg des 
pulmonären Arteriendruckes in hypoxischen tg6 Mäusen im Vergleich zu den 
Kontrollen (wt). Plethysmographische Analysen und Blutgasbestimmungen ergaben 
eine beeinträchtigte Atmung und Sauerstoffsättigung des Blutes. Lungengewebe von 
hypoxischen tg6 Mäusen zeigte eine erhöhte HIF-1α und -2α Stabilisierung und HIF 
Bindungsaktivität. Wenn man hypoxisches Lungengewebe von tg6 und wt Tieren 
vergleicht, beobachtet man keine Veränderung in der mRNA Expression der drei 
Prolyl-hydroxylasen, den wichtigsten Modulatoren der HIF Stabilisierung. 
Interessanterweise war die eNOS mRNA in tg6 Mäusen erhöht, währenddem der NO 
Synthase Hemmer L-NAME den Anstieg von HIF-1α und HIF-2α Protein in der Lunge 
von hypoxischen tg6 Mäusen stärker reduzierte als in wt. Wir haben die tg6 mit wt 
Tieren ersetzt, die wir mit rekombinantem humanem Epo behandelt haben. Da wir 
keinen Unterschied zwischen Epo-behandelten und unbehandelten wt Mäusen 
beobachtet haben, folgern wir, dass der protektive Effekt von Epo in hypoxischen tg6 
Mäusen kein akuter Effekt von Epo darstellt, sondern das Ergebnis von 
Anpassungsmechanismen aufgrund der Epo-induzierten chronischen exzessiven 
Erythrozytose. 
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3. Introduction 
 
Chronic alveolar hypoxia occurring at high altitude (above 2500m) or in chronic 
respiratory or cardiorespiratory diseases such as emphysema, chronic bronchitis or 
cystic fibrosis might lead to pulmonary hypertension (Wagner 2001; León-Velarde 
2008). This is due to the fact that decreased levels of alveolar oxygen concentrations 
can cause vasoconstriction in the pulmonary circulation. During prolonged hypoxia, 
an imbalance in the release of vasoactive substances and an increase in 
muscularisation in the small pulmonary arteries (media hypertrophy) might occur, 
leading to an increased pulmonary vascular resistance and sustained elevation of 
pulmonary arterial pressure (Arias Stella 1963; Meyrick 1980; Reid 1986; Lüscher 
1990; Matsuoka 2001). With time the resulting pulmonary hypertension will lead to 
right ventricular hypertrophy (Peñaloza 1971; Meyrick 2001; Weissmann 2001). As a 
consequence, impaired blood oxygenation and tissue hypoxia will occur. The exact 
mechanisms of pulmonary hypertension are not fully understood, but a variety of 
factors, including hypoxia, erythropoietin (Epo), vasoactive substances (particularly 
nitric oxide), pulmonary vascular remodelling, and altered reactivity of the pulmonary 
vasculature have been implicated in the disease process. In the present study we 
investigated the influence of high Epo plasma levels in the development of hypoxia-
induced pulmonary hypertension. 
 
Epo is a pleiotropic cytokine that is upregulated during prolonged alveolar hypoxia 
and enhances erythropoiesis (Eckardt 2005; Sasaki 2003; Fandrey 2004; Stockmann 
2006). Binding of Epo to its receptor on the erythrocyte progenitor cells present in the 
bone marrow maintains the viability of the cells, promotes cell division, and increases 
the haemoglobin synthesis followed by increased haematocrit levels (Fisher 2003; 
Jelkmann 2005). Epo therefore improves the oxygen carrying capacity of the blood, 
which in turn supports coping with low inspired oxygen concentrations. Interestingly, 
Epo also has several non-erythropoietic functions (Gassmann 2003). Many recent 
studies have shown that Epo has a protective function in the heart (Brines 2004; 
Parsa 2004; Shi 2004; Joyeux-Faure 2005; Joyeux-Faure 2007; Bahlmann 2008) 
and in several neural stroke models (Gassmann 2003; Brines 2004; Ghezzi 2004; 
Marti 2004). A neuroprotective role of Epo in light-induced retinal degeneration 
(Grimm 2002; Grimm 2004; Kilic 2005) and mechanical and ischemic injury of the 
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spinal cord (Gorio 2002; Celik 2002) has also been reported. Moreover, we have 
recently demonstrated that Epo expressed in the brain also affects the neural 
cardiorespiratory network by increasing hypoxic minute ventilation (Soliz 2005; Soliz 
2007b) and by doing so improves oxygenation during hypoxia. Unfortunately, despite 
the beneficial effects, excessive erythrocytosis caused by Epo also has a 
pathological impact. The increased haematocrit might lead to high blood viscosity 
and therefore to a higher risk of cardiovascular disorders such as life-threatening 
cyanosis, hyperaemia, pulmonary hypertension and a high risk of thrombosis (Monge 
1976; Vogel 2003; Reeves 2004; Heinicke 2006). 
 
To further investigate the role of Epo and excessive erythrocytosis in the 
development of pulmonary hypertension, we used a transgenic mouse line (tg6 
mouse). These mice develop chronic excessive erythrocytosis due to a constitutive 
overexpression of human Epo (Ruschitzka 2000; Wagner 2001; Heinicke 2006; Soliz 
2007a) that results in haematocrit values of up to 0.89. This leads to an increased 
blood volume (Ruschitzka 2000; Wagner 2001; Shibata 2003; Vogel 2003) and 
elevated central venous and pulmonary artery pressure (Ruschitzka 2000; Wagner 
2001). Surprisingly, tg6 mice do not show an increase in arterial blood pressure, no 
right ventricular hypertrophy and no increased muscularisation of the pulmonary 
vasculature. They have a normal blood pressure, heart rate and cardiac output 
(Ruschitzka 2000; Wagner 2001; Vogel 2003). Furthermore, there is no increased 
risk of thrombosis (Wiessner 2001; Shibata 2003). The excessive erythrocytosis in 
tg6 mice therefore leads to an elevated pulmonary artery pressure but not to other 
problems found in animals with hypoxia-induced pulmonary hypertension. We 
postulate that this is due to an adaptation to the high haematocrit levels as a result of 
the slow development of erythrocytosis over the first weeks during the animal’s 
growth (Wagner 2001). Tg6 mice show increased expression of endothelial nitric 
oxide synthase (eNOS) in the endothelial cells of the pulmonary arteries, thereby 
leading to elevated synthesis of nitric oxide (NO) (Ruschitzka 2000; Hasegawa 
2004). This could be due to the increased Epo levels, as others have reported that 
Epo could have a direct activating effect on NO synthase in endothelial cells 
(Yamane 1999; Banarjee 2000). It has been shown, that tg6 survival critically 
depends on NO bioavailability (Ruschitzka 2000; Hasegawa 2004). In turn, NO 
induces vasorelaxation and inhibits platelet activation (Ruschitzka 2000) despite the 
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increased endothelin-1 levels in endothelial cells of tg6 mice (Quaschning 2003). 
Apart from the NO-mediated vasodilatation, it was demonstrated that adaptation to 
excessive erythrocytosis in tg6 mice also includes regulation of blood viscosity by 
improving the red blood cell deformability and most probably aggregation (Starzyk 
1999; Vogel 2003; Vogel 2004). Furthermore, the portion of large vessels is 
increased whereas the portion of small vessels is decreased. Also, the vessels have 
reduced pulmonary vascular smooth muscle thickness (Weissmann 2005). In this 
way, the transgenic animals manage to reduce vascular tone and responsiveness. 
Since Epo, high haematocrit levels, NO and endothelin-1 are believed to be involved 
in the effects of hypoxia in the lung (Grimminger 1995; Durmowicz 1999), structural 
and functional adaptations to hypoxia in the pulmonary circulation are probably 
altered in tg6 mice compared to wt mice, with tg6 mice exhibiting anti-pulmonary 
hypertensive effects (Weissmann 2005). Since in chronic pulmonary disease both, 
hypoxemia and polycythaemia are simultaneously present, their individual effects on 
the development of pulmonary hypertension are difficult to define. The tg6 mouse 
model allows us to distinguish between direct effects of hypoxia and secondary 
hypoxic effects due to the excessive erythrocytosis. To distinguish between direct 
effects of Epo and effects due to the increased haematocrit that follows high Epo 
plasma levels, we compared tg6 mice to wild-type (wt) mice and wt mice treated with 
recombinant human Epo (rhEpo) prior to the experiments. 
 
Epo synthesis induced by low oxygen supply to the tissue is regulated by 
transcription factors hypoxia-inducible factor-1 and 2 alpha (HIF-1α and HIF-2α) that 
bind to the HIF binding site on the Epo gene and thereby induce the transcription of 
Epo (Jewell 2001). HIF-α subunits are constitutively expressed but under normoxic 
conditions they are quickly degraded by the ubiquitin-proteasome pathway. The 
proteosomal degradation of HIF-α subunits is induced by a Fe2+-dependent 
hydroxylation of specific prolyl residues within the oxygen-dependent degradation 
domain of HIF-α subunits caused by prolyl-hydroxylases (PHDs). The activity of the 
PHDs depends on the availability of oxygen and is decreased under hypoxic 
conditions (Epstein 2001; Stroka 2001). PHDs therefore appear as today’s best 
candidates for cellular HIF oxygen sensors (Fandrey 2006). Under hypoxic 
conditions, HIF-α subunits are stabilised and heterodimerize with the constitutively 
expressed HIF-1β subunits and form the HIF complexes, which move into the 
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nucleus and bind to the HIF-binding sites of HIF target genes (Semenza 2002; 
Wenger 2002). More than 70 HIF target genes are known (Wenger 2005), all of them 
stimulating either the anaerobic energy production via glycolysis or improving the 
tissue oxygenation by stimulating angiogenesis, vasodilatation or erythropoiesis and 
ultimately help to cope with hypoxia. 
 
To evaluate the impact of Epo and excessive erythrocytosis on the development of 
hypoxia-induced pulmonary hypertension we performed haemodynamic 
measurements, measuring the right ventricular systolic pressure (RVSP) under 
normoxic and hypoxic conditions in tg6 mice, wt mice and wt mice treated with rhEpo 
prior to the measurements. As expected, we recorded a higher RVSP in tg6 mice 
compared to wt mice under normoxic conditions. Because RVSP influences the gas 
exchange in the lung, blood gas analysis showed that tg6 mice have an impaired gas 
exchange or ventilation. To study this phenomenon, we also analysed the ventilation 
of tg6 mice compared to wt mice. To study the impact of decreased blood 
oxygenation of tg6 mice on lung tissue, we measured mRNA and protein levels of 
HIF, the HIF binding activity, the levels of PHD1, 2 and 3 mRNA and also eNOS 
mRNA in lung tissue. 
The data obtained in the present study suggest that excessive erythrocytosis, which 
represents a secondary effect of Epo, influences the development of pulmonary 
hypertension, but not Epo itself. 
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4. Materials and Methods 
 
All animal experiments were performed in accordance with Swiss animal protection 
laws and Zurich University institutional guidelines and conform to the Guide for the 
Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996). 
 
4.1 Transgenic mice 
 
The transgenic mouse line was generated by pronuclear injection of the full-length 
human Epo cDNA driven by the human platelet-derived growth factor (PDGF) B-
chain promoter and has been described previously (Ruschitzka 2000). The resulting 
mouse line TgN(PDGFBEPO)321ZbZ (tg6) was bred by mating hemizygous males to 
wild-type (wt) C57BL/6 females. Half of the offspring was hemizygous for the 
transgene, and the other half was wt and served as control. For the experiments we 
took only female mice, and they were used at three month of age. 
 
4.2 Haemodynamic measurements 
 
For the haemodynamic measurements, the animals were anaesthetised by 1.5% 
isoflurane and a catheter was placed in the right femoral vein. Thereafter, 
anaesthesia was maintained by continuous infusion of etomidate (10 mg/kg/h). Right 
ventricular pressure was measured in closed-chest spontaneously breathing mice as 
previously described (Deten 2004). Briefly, an ultra miniature catheter pressure 
transducer (2F model SPR-612, Millar Instruments Inc., Houston, TX, USA) was 
inserted into the right jugular vein and advanced into the RV via the right atrium. 
Room air was supplied via a nose mask. After a short stabilisation period of about 10 
min, hypoxia was generated through mixing nitrogen and inspiratory air by a pump 
(DIGAMIX 6KM301, Wösthoff Messtechnik GmbH, Germany), starting with a 
reduction of the fraction of inspired O2 (FiO2) to 18%. Thereafter, inspiratory oxygen 
concentration was further reduced by 2% every 7 min and RV function was 
continuously recorded. 
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4.3 Blood gas analyses 
 
Blood gas was measured in animals that have been used for the haemodynamic 
measurements. 7 min after reaching the inspiratory oxygen concentration of 10% or 
6%, the mice were euthanized. Arterial blood was drawn from a catheter placed in 
the right carotid artery and blood gas analysis was performed immediately on a 
bloody machine (Stat Profile, pHOx-Serie, Nova Biomedical, Labor Systeme Flükiger 
AG, Switzerland) according to manufacturer’s instructions. 
 
4.4 Ventilatory measurements 
 
A whole-body flow-though plethysmograph (EMKA Technologies, France) was used 
to monitor ventilation as described (Soliz 2005). Briefly, mice were placed in a 600 ml 
chamber continuously supplied with airflow at 0.7-0.8 l min-1 using flow restrictors. 
Ventilation (VE) was calculated as the product of tidal volume (VT) and respiratory 
frequency (fR) and normalized to 100 g of body weight. Ventilatory measurements 
were performed in normoxia (21% O2) and acute hypoxia achieved by flushing air 
balanced in N2. The FiO2 in the chamber was gradually decreased from 21% to 10% 
O2 during 15 min. Respiratory recordings at 10% O2 were performed for 6 h. 
 
4.5 Hypoxic exposure 
 
Mice were exposed to hypoxia in an Invivo2 1000 hypoxic workstation (Ruskinn, UK). 
After placing the cages containing the animals in the workstation and a short 
adaptation period the oxygen concentration was gradually reduced by 2% every 10 
min until the desired oxygen concentration was reached. At the end of the hypoxic 
exposure period mice were sacrificed by cervical dislocation. Thereafter, the thorax 
was quickly opened and the lung was frozen in liquid nitrogen for later mRNA and 
protein analyses. The duration of the tissue extraction procedure was about 30 – 40 s 
with little variation. In order to assure best comparability, each lobe of the lung was 
stored separately and corresponding whole lobes were used for each analysis, i.e. 
Western blot, EMSA, mRNA expression (see below). 
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4.6 Drug application 
 
Recombinant human Epo (5.000 U/kg, s.c.) or L-NAME (50mg/kg, i.p.) was applied 
30 min prior to hypoxic exposure. 
 
4.7 Protein extraction 
 
The tissue samples were homogenized in lysis buffer (10 mM Tris-HCl (pH 7.5), 1.5 
mM MgCl2, 10 mM KCl mixed with protease inhibitors (Protease Inhibitor Cocktail 
(Calbiochem, USA), 1mM Vanadate, 0.5 MM PMSF, 0.5 mM DDT) with the Ultra-
Turrax (IKA, Faust, Switzerland). Then the samples were homogenized in a glass 
douncer with a tight-fitting pestle for 30 strokes on ice and centrifuged at 1000 x g for 
5 min. The nuclear pellets were resuspended in nuclear extraction buffer (20 mM 
Tris-HCl (pH 7.5), 1.5 mM MgCl2, 420 mM KCl, 20% Glycerol mixed with protease 
inhibitors), rotated for 30 min at 4°C and then centrifuged for 30 min at 13.000 x g. 
The protein concentrations were measured with the BioRad Protein Assay. 
 
4.8 Western blot analysis 
 
Nuclear protein extracts (50 μg) were separated by denaturing SDS-page and 
transferred to a nitrocellulose membrane. After blocking with 5% non-fat dry milk in 
TBS, the membranes were incubated overnight at 4 °C with the primary antibody, 
HIF-1α and HIF-2α (both Novus biologicals, USA) at a dilution of 1:500 and 1:1000, 
respectively. The membranes were washed with TBS containing 0.05% Tween and 
incubated for 1 h at room temperature with the hrp-conjugated secondary antibody 
(Jackson Immuno Research Laboratories, USA, 1:5000). The membranes were then 
incubated with a luminol reaction solution (100mM Tris-HCl (pH 8.5), 0.1 mM 
coumaric acid, 0.625 mM luminol) and exposed to the Luminescent Image Analyzer 
LAS-3000 (Bucher Biotec AG, Switzerland). For normalisation, the blots were 
stripped in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 0.7% β-Mercaptoethanol at 50 °C for 
5 – 15 min and subsequently reprobed for SP-1 (Santa Cruz Biotechnology, 
Germany, 1:500). The digital images were quantified by Quantity One software (Bio-
Rad Laboratories AG, Switzerland). 
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4.9 Electrophoretic mobility shift assay (EMSA) 
 
Positive and negative strands of W18 and M18 oligonucleotide (Integrated DNA 
Technologies, USA), were annealed at 95 °C for 1 min. The double stranded W18 
oligonucleotides were labelled by T4 polynucleotide kinase (Fermentas, Lab Force 
AG, Switzerland) using 50 μCi [γ -32P]-ATP. Unincorporated dsDNA were removed 
by filtration over DNA Quick Spin Column (Sephadex G-25, Roche Diagnostics, 
USA). Pre- and postcolumn samples were counted in a Liquid Scintillation Analyzer 
(Canberra Packard, Switzerland). For the EMSA, 5 μg nuclear protein extract was 
mixed with 0.4 - 0.7 ng 32P-labelled W18 probe, 1 μg M18 probe, and 75 ng Poly dI-
dC in DNA binding buffer and incubated for 20 min at room temperature. Thereafter, 
a 5% non-denaturing polyacrylamide gel electrophoresis was performed at 300 V and 
4 °C, the gel was dried and the probes were visualized using a Molecular Imager FX 
(Bio-Rad Laboratories AG, Switzerland). Specifity was verified by competition with 
unlabeled W18 oligonucleotides and supershift with HIF-1α antibody. 
 
4.10 RNA extraction 
 
Total RNA was isolated using the Trizol-Reagent (Invitrogen, USA) according to the 
protocol supplied by the manufacturer. RNA concentrations were determined 
spectrophotometrically, and RNA integrity was monitored by denaturing 
formaldehyde/agarose gel electrophoresis. 
 
4.11 Quantitative real-time PCR 
 
For quantitative real-time PCR, 5 μg total RNA was reversely transcribed using 
oligo(dT) and reverse transcriptase (Invitrogen, USA) according to the protocol 
supplied by the manufacturer. The mRNA levels of PHD1, PHD2 and PHD3 as well 
as of HIF-1α (forward and reverse primer TCAAGTCAGCAACGTGGAAG and 
CGGCTCATAACCCATCAACT, respectively) and HIF-2α (forward and reverse 
primer TGAAGCTGAGGCCGACCA and GCCGACTTGAGGTTGACAG, respectively) 
were quantified with 5 μl of diluted cDNA reaction (corresponding to 2.5% of cDNA 
reaction) using a SybrGreen qPCR reagent kit (SIGMA-ALDRICH, Switzerland) in 
combination with an ABI 7500 FAST light cycler (Applied Biosystems, Switzerland). 
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Initial template concentrations of each sample were calculated by comparison with 
serial dilutions of a calibrated standard. To control for equal input levels, ribosomal 
protein S12 mRNA was determined, and data were expressed as ratios relative to 
S12 levels. Melting point analyses and agarose gel electrophoresis of amplified PCR 
products were performed to quantify mRNA levels of eNOS by using 5 μl of diluted 
cDNA reaction (corresponding to 2.5% of cDNA reaction) and TaqMan Fast Universal 
PCR Master Mix in combination with an ABI 7500 FAST light cycler (all Applied 
Biosystems, Switzerland). Initial template concentrations of each sample were 
calculated by comparison with serial dilutions of a calibrated standard. To control for 
equal input levels, ribosomal protein S28 mRNA was determined, and data were 
expressed as ratios relative to S28 levels. 
 
4.12 Statistical analyses 
 
One way or two way ANOVA was used, subsequently utilizing the Hom-Sidak post 
hoc procedure (SigmaStat 3.5, Systat Software Inc.). A value of p < 0.05 was 
considered statistically significant. 
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5. Results 
 
5.1 Haemodynamic measurements 
 
Tg6 and wt mice were exposed to gradually decreasing inspiratory oxygen 
concentrations from 21% to 6% oxygen while right ventricular systolic pressure 
(RVSP) and maximal rate of right ventricular pressure increase (RV dP/dtmax) were 
continuously measured. To evaluate whether the measured differences in tg6 and wt 
mice were due to high Epo plasma levels or the resulting excessive erythrocytosis, 
we injected rhEpo in wt mice prior to the experiment. As expected, normoxic RVSP 
and RV dP/dtmax were higher in tg6 mice compared to wt mice (Fig. 1A and Fig. 1B). 
Under hypoxic conditions, RVSP and RV dP/dtmax increased dose-dependently in wt 
mice, and the dose-response curve to decreasing inspired oxygen peaked at 8% O2 
concentration. In tg6 mice, we did not observe a statistically relevant change in RVSP 
and RV dP/dtmax, but we measured the highest values at 12% inspired O2. 
Furthermore, not all of the tg6 mice survived an inspired O2 concentration of 6%. We 
did not see a difference in RVSP and RV dP/dtmax in wt and Epo treated wt mice, 
neither in normoxia nor in hypoxia. 
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Figure 1: Exemplary original recordings (Fig. 1A and Fig. 1B) and haemodynamic data of tg6 and wt 
mice during decreasing inspiratory oxygen concentrations as indicated (Fig. 1C). RVSP: right 
ventricular systolic pressure; RV dP/dtmax: maximal rate of right ventricular pressure increase. 
Numbers of animals at the beginning of the experiment are given in parentheses. Four of the tg6 and 
four of the wt mice were bled after exposure to 10% inspiratory O2 for blood analyses and did not 
complete the experiment. Four additional of the tg6 mice, but none of the wt or Epo treated wt mice, 
did not complete the protocol (one died shortly after reduction of the inspiratory O2 to 10%, one after 
8% and two after 6%). Values in normoxic control mice (room air) did not change over time in both 
genotypes and are not shown in the summary. Data are mean ± SD. * p < 0.05 vs corresponding Nx; † 
p < 0.05 vs corresponding wt. 
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5.2 Blood gas analysis 
 
Eight of the tg6 and eight of wt mice that were used for the haemodynamic 
measurements were euthanized after reaching 10% or 6% inspiratory O2. Blood gas 
analysis was performed immediately after the blood was gained from the catheter 
placed in the right carotid artery. Normoxic animals served as controls. In hypoxia, 
we observed a decrease in pO2, SO2 and pCO2 in both, tg6 and wt mice. Tg6 mice 
had a lower pO2 and SO2 but a higher pCO2 compared to wt mice. 
 
 
 
Figure 2: Blood gas analysis of tg6 and wt mice in normoxia and after 10% or 6% inspiratory oxygen 
concentration. For each group n = 4. Data are mean ± SD. * p < 0.05 vs corresponding Nx; † p < 0.05 
vs corresponding wt. 
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5.3 Analysis of ventilation 
 
Ventilation was measured in normoxia and after exposure to 10% inspiratory O2 for 6 
h by plethysmography. Respiratory frequency (fR) and tidal volume (VT) were 
determined and minute ventilation (VE) was calculated as the product of fR and VT (VE 
= fR * VT). We observed a temporary increase in minute ventilation that was most 
probably due to a temporary increase in breathing rate in wt and tg6 animals, but the 
increase in tg6 mice lasted much longer. After a short adaptation period, the VE of tg6 
mice dropped below the level of wt mice. This could be due to the decrease in tidal 
volume in tg6 mice. 
 
 
 
Figure 3: Ventilatory response of tg6 and wt mice to 10% inspiratory oxygen concentration for 6 h. For 
each group n = 6. Data are mean ± SD. * p < 0.05 vs corresponding Nx; † p < 0.05 vs corresponding 
wt. 
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5.4 mRNA and protein expression of HIF 
 
5.4.1 HIF-1α and HIF-2α mRNA levels in mouse lung (RT-PCR) 
 
Tg6 and wt mice were exposed to 10% inspiratory oxygen concentration for 24 h, and 
normoxic animals served as controls. After removing the lung, we measured mRNA 
expression in this tissue by quantitative real-time PCR. In hypoxia, we observed an 
increase in HIF-1α mRNA in tg6 and wt mice, but no increase in HIF-2α mRNA. HIF-
2α mRNA levels were higher in tg6 than in wt mice under normoxic and hypoxic 
conditions. 
 
 
 
Figure 4: HIF1-α and HIF2-α mRNA expression in mouse lungs in normoxia and in response to 10% 
inspiratory oxygen concentration for 24 h. For each group n = 6. Data are mean ± SD. * p < 0.05 vs 
corresponding Nx; † p < 0.05 vs corresponding wt. 
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5.4.2 HIF-1α and HIF-2α protein levels in mouse lung (Western blot) 
 
Knowing that HIF is mainly regulated at the protein level, we analysed HIF 
stabilisation in hypoxia by measuring HIF protein levels in the lung under normoxic 
and hypoxic conditions. Tg6 and wt mice were exposed to 12%, 10%, 8% and 7% 
inspiratory oxygen concentration for 6 h. To analyse the effect of Epo, we injected 
recombinant human Epo in wt mice prior to hypoxic exposure. In contrast to the 
mRNA measurements shown above, the protein measurements revealed an increase 
of HIF-1α (Fig. 5A) and HIF-2α (Fig. 5B) levels under hypoxic conditions in tg6 and wt 
mice. The increase was more pronounced in tg6 compared to wt animals. As with the 
haemodynamic measurements, we could not detect a difference in HIF protein levels 
in wt and Epo treated wt mice. 
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Figure 5: Representative Western blots of mouse lungs in normoxia and after 6 h at 7% inspiratory 
oxygen concentration and dose-response of HIF-1α (Fig. 5A) and HIF-2α (Fig. 5B) accumulation in 
mouse lung tissue after different inspired oxygen concentrations as indicated for 6 h. The numbers of 
mice tested are 8, 6, 8, and 12 for wt and 4, 3, 4, and 17 for tg6 at 12%, 10%, 8% and 7% O2, 
respectively. n = 6 for Epo treated wt mice and n = 3 for normoxic controls in each group. Data are 
mean ± SD. * p < 0.05 vs corresponding Nx; † p < 0.05 vs corresponding wt. 
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5.4.3 HIF binding activity in mouse lung (EMSA) 
 
To evaluate whether the enhanced stabilisation of HIF results in an increased HIF 
activity, we measured HIF binding activity in normoxia and hypoxia by EMSA. Tg6 
and wt animals were exposed to 7% inspiratory oxygen concentration for 6 h and 
again, wt mice were treated with rhEpo prior to the experiment. As a positive control, 
we used extracts from human Hela cells that produced a fat band slightly above the 
HIF bands of our mice samples. We observed an increase of HIF binding activity in 
tg6 and wt mice under hypoxic conditions. The increase in binding activity was higher 
in tg6 mice compared to wt mice, but there was no difference in wt and Epo treated 
wt mice. 
 
 
 
Figure 6: Representative EMSA and summary of data of HIF binding activity in mouse lung tissue 
after inspiratory oxygen concentration of 7% for 6 h. CTRL: control; C: control extracts from a wt 
mouse (6 h, 6% O2); HC: control extracts from Hela cells (6 h, 1% O2). For each group n = 6. Data are 
mean ± SD. * p < 0.05 vs corresponding Nx; † p < 0.05 vs corresponding wt. 
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5.5 PHD1, PHD2 and PHD3 mRNA levels in mouse lung (RT-PCR) 
 
To investigate whether the difference in HIF expression in tg6 and wt mice could be 
due to different regulation of HIF stabilisation, we measured PHD mRNA levels in 
normoxia and hypoxia by RT-PCR. Tg6 and wt mice were exposed to normoxia and 
to 10% or 8% inspiratory oxygen concentration for 24 h. After hypoxia, we observed 
an increase in PHD3 mRNA in tg6 and wt mice, but not in PHD1 and PHD2. PHD1 
and PHD2 mRNA were only slightly increased after severe hypoxia, but only in tg6 
mice and not in wt mice. PHD mRNA levels of tg6 and wt mice were comparable in 
normoxia and hypoxia. Only PHD1 mRNA levels of tg6 mice were slightly higher than 
the ones in wt mice after severe hypoxia. 
 
 
 
Figure 7: PHD1, PHD2 and PHD3 mRNA expression in mouse lungs in normoxia and in response to 
10% and 8% inspiratory oxygen concentration for 24 h as indicated. For each group n = 6. Data are 
mean ± SD. * p < 0.05 vs corresponding Nx, † p < 0.05 vs corresponding wt. 
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5.6 HIF protein levels upon reoxygenation in mouse lung (Western blot) 
 
Since HIFs are rapidly degraded upon reoxygenation we measured HIF protein levels 
after different time points of reoxygenation. tg6 and wt mice were exposed to 7% 
inspiratory oxygen concentration for 6 h and reoxygenated for up to 20 min. We 
calculated the curve that best fitted the results to define the half life-time (t½) of HIF 
proteins upon reoxygenation. Assuming an exponential curve, the half-life time of 
HIF-1α (Fig. 8A) was slightly shorter in tg6 mice relative to wt mice, whereas the half-
life time of HIF-2α (Fig. 8B) was the same for both, tg6 and wt mice. Comparing HIF-
1α and HIF-2α proteins, we observed only a small difference in the half-life time. 
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Figure 8: Representative Western blots and estimation of HIF-1α (Fig. 8A) and HIF-2α (Fig. 8B) decay 
rate in mouse lungs upon reoxygenation. Mice were kept at 7% inspiratory oxygen concentration for 6 
h. Thereafter, one mouse was sacrificed in the hypoxic workstation (0) and the remaining mice 
removed to room air and sacrificed after 2.5, 5, 7.5, 10 or 20 min as indicated. For each group n = 6. 
The half-life times (solid line for wt and dashed line for tg6 mice, respectively) were calculated based 
on an exponential decay. Data are mean ± SD. 
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5.8 eNOS mRNA in mouse lung (RT-PCR) 
 
Nitric oxide (NO) is one of the strongest vasodilatators known in mammals. 
Considering that tg6 mice have elevated NO levels in pulmonary endothelial cells, we 
investigated the influence of hypoxia on the mRNA expression of the endothelial NO 
synthase (eNOS). We exposed tg6 and wt mice to 10% and 8% inspiratory oxygen 
concentration for 24 h, and normoxic animals served as controls. There was an 
increase of eNOS mRNA under hypoxic conditions, but only at an inspired oxygen 
concentration of 8% but not of 10%, and the increase was higher in tg6 mice 
compared to wt mice. Tg6 mice also showed higher eNOS mRNA concentrations 
than wt mice at an inspired oxygen concentration of 10%. 
 
 
 
Figure 9: mRNA expression of endothelial nitric oxide synthase (eNOS) in mouse lungs in response to 
normoxia and to 10% or 8% inspiratory oxygen concentration for 24 h. For each group n = 6. Data are 
mean ± SD. * p < 0.05 vs corresponding Nx; † p < 0.05 vs corresponding wt. 
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5.7 HIF protein levels in mouse lung after L-NAME treatment (Western blot) 
 
To further investigate the influence of NO on HIF stabilisation, we injected the NO 
synthase inhibitor L-NAME prior to hypoxic exposure. Before measuring HIF protein 
levels, tg6 mice were exposed to 10% and wt mice to 8% of inspiratory oxygen for 6 
h. We observed a reduction of HIF-1α and HIF-2α protein levels through L-NAME 
treatment in hypoxia, and the reduction was stronger in tg6 mice compared to wt 
mice. 
 
 
 33
  
 
 
 
 
Figure 10: Effect of nitric oxide synthase (NOS) inhibition by L-NAME (50mg/kg, i.p.) on HIF-1α and 
HIF-2α protein accumulation in mouse lungs after inspiratory oxygen concentration of 10% (tg6) or 8% 
(wt) for 6 h. Representative Western blots (Fig. 10A) and summary of data (Fig. 10B). CTRL: control. 
Data are mean ± SD. * p < 0.05 vs corresponding Nx; † p < 0.05 vs corresponding wt; ‡ p < 0.05 vs 
corresponding Hx-CTRL. 
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6. Discussion 
 
The results obtained in the current study indicate that compared to wt mice, tg6 mice 
are more resistant to developing pulmonary hypertension in response to hypoxia. 
Interestingly, tg6 mice are at the same time more sensitive to hypoxia, since under 
hypoxic conditions tg6 mice showed impaired ventilation, reduced blood oxygenation, 
and elevated HIF levels to a higher extent than the wt mice. The aim of our study was 
to investigate whether the differences observed in tg6 and wt mice are directly 
caused by Epo or due to the excessive erythrocytosis developing in tg6 mice. 
 
Since RVSP directly reflects the pressure in the lung, we measured RVSP instead of 
pulmonary pressure. We evaluated RVSP in tg6 and wt mice under normoxic and 
hypoxic conditions. Tg6 mice had a higher RVSP and RV dP/dtmax compared to wt 
mice under normoxic conditions. This was not surprising, considering the tremendous 
increase in haematocrit and blood volume reported in tg6 mice (Ruschitzka 2000; 
Wagner 2001; Shibata 2003; Vogel 2003), and it is in agreement with previous 
studies (Deten 2004; Hasegawa 2004). 
Both, RVSP and RV dP/dtmax dose-dependently increased in wt mice during hypoxic 
exposure, whereas the tg6 animals did not show a statistically relevant change of 
either value. Since tg6 mice kept in a normoxic environment have a larger amount of 
medium-sized and large vessels and a higher percentage of non-muscularised 
vessels relative to wt mice (Weissmann 2005), the wall tension in their vessels is 
increased. According to La Place’s equation, this could explain their attenuated 
hypoxic vasoconstriction and smaller increase in RVSP. This is also in line with 
previous reports that describe altered pulmonary vascular reactivity in tg6 mice 
(Hasegawa 2004; Weissmann 2005). NO also plays an important role in controlling 
the vascular tone, and it was shown that NO, among other factors, could attenuate 
hypoxia-induced pulmonary hypertension (Fagan 1999a; Fagan 1999b). Since the 
levels of eNOS and NO are higher in the pulmonary arteries of tg6 mice compared to 
wt mice (Ruschitzka 2000; Hasegawa 2004), a NO-triggered vasodilatation might 
contribute to the lower pulmonary vasoreactivity of tg6 mice. This could be, at least 
partly, the explanation why tg6 mice displayed an attenuated haemodynamic 
response to hypoxia. 
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The dose-response curves for RVSP and RV dP/dtmax of wt mice to decreasing 
inspired oxygen peaked at an oxygen concentration of 8%. In tg6 mice, we did not 
observe an increase in RVSP, but we measured the highest values at 12% inspired 
O2. Furthermore, not all of the tg6 mice survived an inspired oxygen concentration of 
6%. This suggested that tg6 mice are more sensitive to hypoxia than wt mice. This 
observation was surprising, because the decreased vasoreactivity in tg6 mice would 
rather suggest a delayed maximum of the hypoxic pulmonary response curve. Also, 
we would expect an increased tolerance of tg6 mice compared to wt animals to low 
inspiratory oxygen concentrations because of the increased oxygen transport 
capacity due to the elevated haematocrit levels in tg6 mice. 
Since we did not observe a difference in RVSP and RV dP/dtmax in wt and Epo 
treated wt mice, we concluded that Epo most likely does not have a direct effect on 
RVSP. The altered RVSP occurring in tg6 mice compared to wt mice seemed to be a 
result of the excessive erythrocytosis in tg6 mice. This was not due to the high blood 
viscosity though, as previous studies performed in isolated buffer perfused lungs from 
tg6 mice also showed an attenuated hypoxic vasoconstriction (Weissmann 2005). 
 
The blood gas analysis revealed a lower arterial pO2 and SO2 in tg6 relative to wt 
mice, but a higher pCO2. This indicates that tg6 mice have an impaired blood 
oxygenation that could be due to deteriorated gas exchange, reduced ventilation or 
both. The ventilation analysis showed that tg6 and wt mice displayed an increased 
breathing rate and consequently elevated minute ventilation after acute exposure to 
hypoxia. After a short adaptation period, both values returned to normoxic values in 
wt mice. In contrast, minute ventilation of tg6 animals dropped below the one of wt 
controls, probably because of a decrease in tidal volume after prolonged hypoxia. 
These results suggested that tg6 mice have reduced alveolar ventilation under 
hypoxic conditions, an observation that is in line with previous reports showing 
altered ventilatory pattern in tg6 mice (Soliz 2007b). Further studies are required to 
clarify whether this is due to the increased blood volume and erythrocytosis in tg6 
mice or if it is a direct effect of Epo, since Epo itself has been shown to modulate the 
ventilatory response to reduced oxygen (Soliz 2005; Soliz 2007a; Soliz 2007b). The 
impaired blood oxygenation and ventilation in tg6 mice could explain the decreased 
tolerance of tg6 mice to low inspired oxygen concentration seen in the 
haemodynamic measurements. 
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To investigate at the molecular basis whether the reduced blood oxygenation also 
leads to tissue hypoxia, we examined the HIF signalling pathway. 
Measurements of HIF-1α and HIF-2α mRNA revealed an increase of HIF-1α mRNA 
during hypoxic exposure for both tg6 and wt mice, whereas HIF-2α mRNA did not 
change in response to hypoxia. This was in agreement with other studies (Wiener 
1996; Palmer 1998). Whereas the HIF-1α mRNA levels in tg6 and wt mice were 
similar in normoxia and hypoxia, HIF-2α mRNA levels were increased in tg6 animals 
compared to wt controls. 
Assuming that decreased blood oxygenation under hypoxic conditions leads to tissue 
hypoxia we expected an increase in HIF protein in the tissue during hypoxic 
exposure. Indeed, protein measurements revealed an increase in both, HIF-1α and 
HIF-2α protein levels. Furthermore, the increase was more pronounced in tg6 
compared to wt mice for both HIF-1α and HIF-2α. This could be explained by the 
lower arterial pO2 in tg6 mice in hypoxia, which probably leads to a more severe 
tissue hypoxia. The analysis of the binding activity of HIF by EMSA showed an 
increase with hypoxia, too. The increase in binding activity was more pronounced in 
tg6 mice compared to wt mice, as it was for the HIF protein levels. We therefore not 
only showed that hypoxia leads to HIF protein stabilisation in the lungs of both tg6 
and wt mice, but also that the HIF complex was active. Neither protein amount nor 
binding activity of wt mice and Epo treated wt mice were different. Therefore, we 
concluded that high Epo plasma levels do not directly influence the regulation of HIF 
stabilisation. Most probably, secondary effects of Epo are responsible for the 
differences in tg6 and wt mice. 
In contrast to our measurements in the lung, brain tissue from tg6 mice shows lower 
levels of HIF-1α and HIF-2α in hypoxia than tissue from wt mice (Ogunshola 2006). 
This could be due to the fact that tg6 mice have a higher transport capacity of 
oxygen. One explanation for the discrepancy between lung and other tissues could 
be that under hypoxic conditions, oxygen is redirected to vital organs such as the 
brain to optimise their oxygenation. HIF levels in the lung could reflect the reduced 
alveolar oxygen content, which would mean that alveolar epithelial cells are the major 
source of the observed HIF protein in the tissue. Unfortunately, an identification of the 
HIF positive cells in the lung by immunohistochemistry was not successful. 
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To further investigate the differences in HIF stabilisation between tg6 and wt mice, 
we analysed the PHDs, which are known to be the master regulators of HIF and the 
most important cellular oxygen sensing system leading to HIF stabilisation (Fandrey 
2006). We measured the mRNA levels of PHD1, PHD2 and PHD3. The mRNA levels 
of PHD3 were increased in hypoxia for both tg6 and wt mice. This was not surprising, 
because PHD3 and PHD2 are identified as HIF-1α target genes and therefore their 
expression is induced in hypoxia (Metzen 2003; Fandrey 2006). In our experiment, 
PHD2 mRNA levels were elevated only after severe hypoxia and only in tg6 mice, but 
not in wt mice. Unexpected was the small increase of PHD1 mRNA levels after 
severe hypoxia in tg6 mice, because according to the literature PHD1 is not 
influenced by hypoxia (Fandrey 2006). Thus, apart from our PHD1 findings, we did 
not detect any differences in PHD mRNA levels of tg6 and wt mice in normoxia and 
hypoxia. HIF regulation through PHDs therefore did not explain the difference in HIF 
stabilisation in tg6 and wt animals. Due to technical problems, we were not able to 
measure the protein concentrations of PHDs in mouse lung tissue, so instead we 
analysed the activity of the PHD proteins. 
PHD activity is regulated by a number of stimulators and inhibitors including 
numerous metabolites, reactive oxygen species (ROS) and NO (Kaelin 2008). To 
circumvent technical difficulties measuring ROS or NO we investigated the capacity 
of the PHDs to hydroxylate HIF through the measurement of HIF-1α and HIF-2α 
decay rate upon reoxygenation. Considering the short half-life time of HIF upon 
reoxygenation (Huang 1996) and assuming that PHDs are the only factors regulating 
HIF stabilisation, this was a straightforward method for approximating PHD activity. 
The analysis of the data suggested an exponential decay of HIF upon reoxygenation 
and a nearly identical half-life for HIF-1α and HIF-2α proteins in tg6 and wt mice, not 
indicating a reduced PHD activity in tg6 lungs compared to wt lungs. The half-life time 
of HIF-1α was only slightly shorter in tg6 mice relative to wt mice, which could be due 
to the higher PHD1 transcript levels in tg6 mice in severe hypoxia. Comparing HIF-1α 
and HIF-2α, HIF-1α showed a somewhat shorter half-life time than HIF-2α pointing to 
the possibility that HIF-1α is hydroxylated faster by PHDs than HIF-2α. 
 
Apart from regulating the PHD activity, HIF signalling might be modified by an 
elevated NO production. Indeed it has been shown that tg6 mice have elevated 
eNOS and NO levels in the pulmonary artery endothelial cells compared to wt mice 
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(Ruschitzka 2000; Hasegawa 2004). The assumption that NO influences HIF 
signalling is supported by our finding that eNOS mRNA levels were augmented with 
severe hypoxia, and this was more pronounced in tg6 compared to wt animals. We 
did not observe an induction of eNOS mRNA in moderate hypoxia, but eNOS mRNA 
was still higher in tg6 compared to wt animals. To evaluate the effect of inhibiting NO 
synthase, we injected the mice with the NOS- inhibitor L-NAME. This manipulation 
reduced the protein levels of HIF-1α and HIF-2α under hypoxic conditions in tg6 mice 
to a much higher extent than in wt mice. The difference in HIF stabilisation in tg6 and 
wt mice therefore seemed to be at least partly due to changes in NO availability in tg6 
mice. Others have reported that Epo might directly activate eNOS (Yamane 1999, 
Banarjee 2000), but we did not find evidence that Epo directly influences HIF 
stabilisation, since we could not see a difference in wt and Epo treated wt mice. 
 
In summary, we concluded that upon hypoxic exposure tg6 mice have impaired 
ventilation with a reduced tidal volume relative to wt animals. Tg6 mice therefore 
have a more pronounced decrease in alveolar and arterial pO2 followed by an 
impaired blood and tissue oxygenation. This leads to an increased activation of the 
HIF signalling pathway. The enhanced accumulation and activation of HIF in tg6 mice 
seem to be specific for the pulmonary system and linked to the elevated eNOS 
expression and the resulting enhanced NO production in the tg6 lungs. These 
findings suggest a higher sensitivity of tg6 mice to hypoxia and can not be explained 
by systemic elevation of the Epo titer, but are caused by secondary compensatory 
mechanisms to the excessive erythrocytosis following elevated Epo levels in tg6 
animals. The finding that Epo does not directly cause the differences observed in tg6 
and wt mice was also documented earlier. It was reported that the infertility of female 
tg6 mice was not caused directly by Epo but is a result of excessive erythrocytosis 
(Gassmann 2008). Interestingly, patients with polycythemia vera that causes 
excessive erythrocytosis without increased Epo plasma levels do not regularly 
develop pulmonary hypertension. Pulmonary hypertension may be the consequence 
of local thrombosis in the pulmonary vasculature (Nand 1994; Hachulla 2000), 
because a prothrombotic tendency due to the high haematocrit and the elevated 
platelet counts is seen in about 27% of the patients (Dingli 2001). These 
observations suggest that other factors than excessive erythrocytosis and its 
consequences are involved in the development of pulmonary hypertension. 
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To further analyse the effects of Epo, I suggest reducing the haematocrit but not the 
Epo levels in tg6 mice by splenectomy. Since tg6 mice show extramedullary 
erythropoiesis in the spleen, splenectomy reduces the haematocrit from 0.89 to 0.62 
(Vogel 2003). The resulting mice would show adaptations to excessive 
erythrocytosis, but would not have elevated haematocrit values despite the increased 
plasma Epo levels. This would allow distinguishing between direct effects of Epo and 
secondary effects due to different adapting mechanisms to excessive erythrocytosis 
in tg6 mice. Increasing the haematocrit but not the Epo levels in wt mice by blood 
transfusion would also be an exciting experiment. 
It would also be interesting to further investigate the organ-specific differences in HIF 
stabilisation. Besides measuring HIF protein concentrations under normoxic and 
hypoxic conditions in different tissues, it would be important to analyse tissue NO 
concentrations, because NO seems to influence HIF stabilisation. 
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